'Attractive valuation': 2 ASX shares QVE analysts just bought

These stocks have been shocking recently, but the long-term outlook is much better than that suggests.

| More on:
Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

We hear a lot of opinions online about which ASX shares to buy.

But how do you syphon the genuine tips from the voices that are simply filling up the vacuum?

Perhaps there is no greater endorsement for a stock from a professional than one that she or he had actually bought themselves.

They're hardly going to buy ASX shares that will endanger their own or their clients' money, are they? That would be a career killer.

As such, we note with much interest two stocks that the analysts at QVE are bullish on and have recently bought:

A 'resilient' business for economic turbulence

Both Amcor CDI (ASX: AMC) and Mayne Pharma Group Ltd (ASX: MYX) shares are in a funk at the moment.

The Mayne stock price has dropped almost 9% since 8 May, while Amcor has shed 8.8% of its valuation since 2 May.

Yet the QVE team has taken the opportunity to buy more of these stocks.

In a memo to clients, it explained that Amcor shares plunged in May after a third-quarter update indicated "customer destocking coming out of elevated inventories during COVID saw lower volumes across its Rigids and Flexibles divisions".

But that shouldn't deter long-term investors.

"While disappointing, the defensive nature of packaging demand means Amcor should be relatively resilient through the impending slowdown in economic activity, while the valuation remains attractive."

Amcor shares have largely gone sideways in recent times, trading about 7% lower than they did five years ago.

'Strong cash position and low valuation'

Similarly, Mayne Pharma stocks also plummeted last month upon management announcing "the current year's profit would be below expectations due to an increase in marketing costs".

This is despite "improved sales performances" for its flagship female health drug Nextellis and "a recovery in earnings of its dermatology division".

Mayne shares have been a bit of a disaster in recent years, losing almost 80% of its value over the past five years.

The pharmaceutical stock is now trading at a price-to-sales ratio of just 1, which the directors are apparently cognisant of.

"Given its strong cash position and low valuation, the board also announced an on-market buyback."

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Amcor Plc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Two workers at an oil rig discuss operations.
Broker Notes

Should you buy Santos, Beach Energy or Woodside shares? Here's Macquarie's top pick

Macquarie has released its new share price expectations for Santos, Beach Energy and Woodside shares.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

person holding hat
Broker Notes

3 ASX 200 large-cap shares just re-rated by analysts

We reveal the latest views on an ASX 200 large-cap miner, retailer, and consumer staples leader.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Down 80% in 2025: Is it time to buy this beaten down ASX stock?

Let's see what Bell Potter is saying about this stock after its heavy decline.

Read more »

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Broker Notes

NextDC shares jump 11% on major OpenAI deal

This data centre operator will be home to the AI giant in Australia.

Read more »

A large clear wine glass on the left of the image filled with fifty dollar notes on a timber table with a wine cellar or cabinet with bottles in the background.
Broker Notes

Macquarie names 3 top dividend-paying ASX 200 shares to buy today

Macquarie expects these three dividend paying ASX 200 shares to outperform in 2026. Let’s see why.

Read more »

Confident male executive dressed in a dark blue suit leans against a doorway with his arms crossed in the corporate office
Broker Notes

Broker reveals ratings on 4 ASX 200 sector leaders

Prefer ASX 200 large-cap stocks? Here are some new ratings and price targets for four sector leaders.

Read more »

A young boy points and smiles as he eats fried chicken.
Broker Notes

Why brokers are bullish on this rapidly-growing ASX 200 share

This business is delivering tasty earnings growth…

Read more »